Up | AC
Home Page
Food and
Drug Administration
Oncologic Drugs
Advisory Committee
May 30, 2008
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §
552).
FDA Briefing Material (pdf)
GlaxoSmithKline
Inc.
Disclaimer
The statements contained in this document(s) are those of
the product's sponsor, not FDA, and FDA does not necessarily agree with the
sponsor's statements. FDA has not made a final determination about the safety
or effectiveness of the product described in this document.
Briefing Material (pdf)